Document is current
Any future updates will be listed below
-
Authors
Reay, William R. https://orcid.org/0000-0001-7689-2453
Geaghan, Michael P.
,
Agee, Michelle
Alipanahi, Babak
Bell, Robert K.
Bryc, Katarzyna
Elson, Sarah L.
Fontanillas, Pierre
Furlotte, Nicholas A.
Hicks, Barry
Hinds, David A.
Huber, Karen E.
Jewett, Ethan M.
Jiang, Yunxuan
Kleinman, Aaron
Lin, Keng-Han
Litterman, Nadia K.
McCreight, Jey C.
McIntyre, Matthew H.
McManus, Kimberly F.
Mountain, Joanna L.
Noblin, Elizabeth S.
Northover, Carrie A. M.
Pitts, Steven J.
Poznik, G. David
Sathirapongsasuti, J. Fah
Shelton, Janie F.
Shringarpure, Suyash
Tian, Chao
Tung, Joyce Y.
Vacic, Vladimir
Wang, Xin
Wilson, Catherine H.
Cairns, Murray J. https://orcid.org/0000-0003-2490-2538
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1121474, 1147644)
- License Information
-
More Information
Article History
Received: 9 February 2021
Accepted: 17 June 2022
First Online: 29 June 2022
Competing interests
: The 23andMe research consortia team authors were/are employed by 23andMe, Inc., and own stock or stock options in 23andMe, Inc. W.R.R. and M.J.C. have filed a patent related to the use of the pharmagenic enrichment score framework in complex disorders (WIPO Patent Application WO/2020/237314), an approach used in a section of this study. W.R.R. and M.J.C. also are directors of a company that aims to commercialise the pharmagenic enrichment score platform (PolygenRx Pty Ltd). The remaining authors declare no competing interests.
